TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AMGN

Amgen Inc. - Common Stock

NASDAQ
$435.64
▼ $3.30 (-0.8%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $483.99L $320.97+33.5%
$483.99$451.39$418.78$386.18$353.57$320.97$435.64
RSI (14)
Intraday · 15-minSell-35RSI 34DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Strong buy+50
RSI (14)41
oversold 30overbought 70
Trend
Uptrend
MACD
Bearish
Bollinger
Below lower band
vs 20-day
below
vs 50-day
above
vs 200-day
above
Support
$434.51
Resistance
$483.99
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
+13.3%
Buy & hold
+16.2%
Trades
3
Win rate
33%

$100,000.00 invested would be worth $113,323.92 (+13.3%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Amgen Inc.· Drug Manufacturers - General

source: yahoo

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
31,500

Fundamentals

source: yahoo
Market cap
$235.64B
P/E
25.3
P/B
16.4
EPS
$17.25
Div yield
2.3%
Profit margin
24.1%
ROE
78.4%
Debt / Equity
3.76
Beta
0.42
52-week range
$312.39 – $483.99
52-week low · $312.3972% of rangehigh · $483.99

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive2↑ · 0↓ · 6–
  • Mizuho Adjusts Price Target on Amgen to $388 From $352, Maintains Neutral Rating— Neutral
    MT Newswires · 20 Nov 2026
  • Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know— Neutral
    Zacks · 20 Nov 2026
  • What SPDR Dow Jones Industrial Avg ETF (DIA) Bought: Goldman Leads on Nov. 18— Neutral
    GuruFocus.com · 20 Nov 2026
  • Amgen Inc's Dividend Analysis
  • Price is below the lower Bollinger Band (stretched to the downside).
  • Educational technical indicators — not investment advice. TradeOrgs does not place trades.

    Headquarters
    Thousand Oaks, United States
    www.amgen.com ↗
    ▲ Positive
    GuruFocus.com · 20 Nov 2026
  • Securitize Adds Anthropic to Tokenized Stock Platform— Neutral
    MT Newswires · 19 Nov 2026
  • Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target▲ Positive
    Proactive · 19 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.